Stéphane Bancel, Moderna CEO (Joel Saget/AFP via Getty Images)
January 9, 2023 04:55 PM ESTUpdated January 10, 10:24 AM
Pharma
Coronavirus

Up­dat­ed: Mod­er­na rounds out 2022 with $18.4B in vac­cine sales, boosts R&D bud­get for 2023

Nicole DeFeudis

Editor

Mod­er­na CEO Stéphane Ban­cel is revving the en­gines go­ing in­to 2023, with a whop­ping $4.5 bil­lion R&D bud­get and a new pri­or­i­ty re­view vouch­er. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times